Prasugrel Mylan

RSS

prasugrel

Authorised
This medicine is authorised for use in the European Union.

Overview

Prasugrel Mylan is taken together with aspirin to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) in patients with acute coronary syndrome who are undergoing percutaneous coronary intervention. Acute coronary syndrome is a group of conditions in which blood supply in the vessels supplying the heart is interrupted so heart tissue cannot work properly or dies. It includes unstable angina (a severe type of chest pain) and heart attack. Percutaneous coronary intervention is a procedure used to unblock the blood vessels supplying the heart.

Prasugrel Mylan contains the active substance prasugrel and is a ‘generic medicine’. This means that Prasugrel Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Efient.

This EPAR was last updated on 28/06/2022

Authorisation details

Product details
Name
Prasugrel Mylan
Agency product number
EMEA/H/C/004644
Active substance
prasugrel besilate
International non-proprietary name (INN) or common name
prasugrel
Therapeutic area (MeSH)
  • Myocardial Infarction
  • Acute Coronary Syndrome
  • Angina, Unstable
Anatomical therapeutic chemical (ATC) code
B01AC22
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Mylan Pharmaceuticals Limited
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
15/05/2018
Contact address

Mylan Pharmaceuticals Limited
Damastown Industrial Park
Mulhuddart
Dublin 15
Ireland

Product information

25/05/2022 Prasugrel Mylan - EMEA/H/C/004644 - N/0010

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Prasugrel Mylan, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).

Assessment history

How useful was this page?

Add your rating
Average
2 ratings